Stay updated on Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0 on the page.
    Difference
    0.1%
    Check dated 2026-03-19T06:25:22.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision label updated to v3.4.3, replacing the previous v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-12T02:32:52.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2; no visible changes to the study details, eligibility criteria, or contacts were identified. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-11T11:31:58.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    The update shows a minor version bump from v3.4.0 to v3.4.1 with no user-facing changes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T10:16:51.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Added a Show glossary toggle and new metadata fields (Last Update Submitted that Met QC Criteria) plus a No FEAR Act Data note and a Revision: v3.4.0. These are UI and metadata updates that do not change the core study content or enrollment details.
    Difference
    0.2%
    Check dated 2026-01-28T05:55:34.000Z thumbnail image
  8. Check
    67 days ago
    Change Detected
    Summary
    Revision label on the page updated from v3.3.3 to v3.3.4; no substantive study content was altered. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T03:48:28.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Triple Negative Breast Cancer Clinical Trial page.